Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12074MR)

This product GTTS-WQ12074MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12074MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8871MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ6468MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ5839MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ10862MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ5924MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ10747MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ9605MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ14470MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW